Shares of bluebird bio Inc (NASDAQ:BLUE) were up 0% on Wednesday . The company traded as high as $180.50 and last traded at $175.25. Approximately 1,806,307 shares were traded during trading, an increase of 115% from the average daily volume of 841,200 shares. The stock had previously closed at $175.25.

A number of analysts recently weighed in on BLUE shares. Cantor Fitzgerald restated a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research note on Thursday, September 28th. Leerink Swann reiterated an “outperform” rating and issued a $120.00 price target on shares of bluebird bio in a research note on Saturday, September 30th. Morgan Stanley lowered shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price target on the stock. in a research note on Monday, October 2nd. Goldman Sachs Group reiterated a “buy” rating and issued a $186.00 price target on shares of bluebird bio in a research note on Friday, October 6th. Finally, Maxim Group reiterated a “buy” rating and issued a $170.00 price target (up from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $157.45.

The company has a market capitalization of $8,030.00, a PE ratio of -25.00 and a beta of 2.08.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 27.00% and a negative net margin of 1,021.98%. The business’s revenue was up 397.4% on a year-over-year basis. During the same quarter last year, the business posted ($2.07) earnings per share. analysts expect that bluebird bio Inc will post -6.72 earnings per share for the current year.

In other news, COO Susanna Gatti High sold 1,282 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the transaction, the chief operating officer now directly owns 13,718 shares in the company, valued at $2,361,553.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Nick Leschly sold 3,350 shares of the firm’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $145.02, for a total transaction of $485,817.00. Following the transaction, the chief executive officer now owns 259,059 shares in the company, valued at $37,568,736.18. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,445 shares of company stock worth $37,326,831. Insiders own 3.90% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of BLUE. QS Investors LLC lifted its holdings in shares of bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares during the period. Biondo Investment Advisors LLC acquired a new stake in shares of bluebird bio during the third quarter worth $203,000. SG Americas Securities LLC lifted its holdings in shares of bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 295 shares during the period. Finally, Fairfield Bush & CO. acquired a new stake in shares of bluebird bio during the second quarter worth $210,000.

ILLEGAL ACTIVITY WARNING: “bluebird bio (BLUE) Trading Up 0%” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/17/bluebird-bio-blue-trading-up-0.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.